

Alicante, 15 October 2026

COMMUNICATION – MARKET NOTICE – FACEPHI BIOMETRIA, S.A.

Dear Sirs,

Pursuant to Article 17 of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (Market Abuse Regulation), and section 4.5.1 of Euronext Growth Markets Rule Book Part I: Harmonized Rules, on ongoing obligations of companies listed on Euronext, (hereinafter "Facephi" or "the Company") hereby notifies the following:

The Company hereby announces that the Alternative Fixed Income Market ("MARF") has admitted the "Facephi 2026 Commercial Paper Programme" (the "Programme"), with a maximum outstanding nominal amount of twenty million euros (€20,000,000) and a term of 12 months.

The Company has appointed GVC Gaesco Valores, S.V., S.A. as the Programme's registered adviser, and GVC Gaesco Valores and PKF Attest Capital Markets, S.V., S.A. as collaborating entities. Ramón y Cajal Abogados, S.L.P. has acted as legal adviser to the transaction.

Facephi has a long-term credit rating of BB- with an evolving outlook, assigned by Ethifinance Ratings on 30 July 2026.

The Base Information Document for Admission is duly published on the MARF website: [MARF Admits the Facephi 2026 Commercial Paper Programme for 20 Million Euros | BME Bolsas y Mercados Españoles](#)

We remain at your disposal for any clarification you might deem necessary.

Sincerely,

Javier Mira Miró

Chairman of the Board of Directors